Absci Reports Q3 2026 Financials, Trial Progress, New Hire

VANCOUVER, Wash. and NEW YORK, Nov. 12, 2026 /CourierPR/ -- Absci Corporation, a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, has reported its financial and operating results for the quarter ended September 30, 2026. The company's financial performance for the quarter shows a revenue of $0.3 million, down from $0.4 million in the corresponding period of the previous year. Research and development expenses increased to $23.6 million for the quarter, up from $19.2 million in the previous year, primarily due to the advancement of Absci's internal programs, including direct costs associated with external nonclinical and clinical development of ABS-201, offset by a decrease in personnel-related costs. Selling, general, and administrative expenses for the quarter were $9.0 million, up from $8.4 million in the previous year, driven by stock-based compensation.

Absci's financial results reflect the company's continued focus on advancing its internal pipeline programs, including the ongoing development of ABS-201 for pattern hair loss and endometriosis. The company anticipates reporting 13-week interim proof-of-concept data for ABS-201 in December 2026 and full 26-week proof-of-concept data in early 2027. The trial is progressing on track, with the company planning to initiate a Phase 2 clinical trial for ABS-201 in endometriosis in mid-2027. The trial will be a double-blind, randomized, placebo-controlled study assessing the efficacy and safety of ABS-201 in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) after a run-in period.

In other developments, Absci has appointed former Galderma executive Gerry Muhle as the company's Chief Commercial Officer. Muhle, who brings over 25 years of experience across pharma, aesthetics, and consumer brands, will help Absci build its commercial infrastructure to support its wholly-owned programs. The company's financial results also indicate that its cash, cash equivalents, and marketable securities as of September 30, 2026, were $173.7 million, down from $201.1 million as of June 30, 2026.

Absci's financial results for the quarter ended September 30, 2026, reflect the company's continued focus on advancing its internal pipeline programs, including the ongoing development of ABS-201 for pattern hair loss and endometriosis. The company anticipates reporting 13-week interim proof-of-concept data for ABS-201 in December 2026 and full 26-week proof-of-concept data in early 2027. The trial is progressing on track, with the company planning to initiate a Phase 2 clinical trial for ABS-201 in endometriosis in mid-2027. The trial will be a double-blind, randomized, placebo-controlled study assessing the efficacy and safety of ABS-201 in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) after a run-in period. Absci has also appointed Gerry Muhle as the company's Chief Commercial Officer, bringing over 25 years of experience across pharma, aesthetics, and consumer brands to help Absci build its commercial infrastructure to support its wholly-owned programs. The company's financial results also indicate that its cash, cash equivalents, and marketable securities as of September 30, 2026, were $173.7 million, down from $201.1 million as of June 30, 2026.